Josep M ArgilÃ©s

List of Publications by Year
in descending order

191 papers	16,340 citations	18482 62 h-index	17592 121 g-index
195 all docs	195 docs citations	195 times ranked	14032 citing authors

#	Article	IF	Citations
1	Lack of Synergy Between Î²-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. OncoTargets and Therapy, 2021, Volume 14, 1953-1959.	2.0	1
2	Differential structural features in soleus and gastrocnemius of carnitineâ€treated cancer cachectic rats. Journal of Cellular Physiology, 2020, 235, 526-537.	4.1	10
3	The animal cachexia score (ACASCO). Animal Models and Experimental Medicine, 2019, 2, 201-209.	3.3	9
4	Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. Journal of Molecular Biology, 2019, 431, 2674-2686.	4.2	69
5	Therapeutic strategies against cancer cachexia. European Journal of Translational Myology, 2019, 29, 7960.	1.7	44
6	Mediators of cachexia in cancer patients. Nutrition, 2019, 66, 11-15.	2.4	50
7	Cancer cachexia, a clinical challenge. Current Opinion in Oncology, 2019, 31, 286-290.	2.4	18
8	Inter-tissue communication in cancer cachexia. Nature Reviews Endocrinology, 2019, 15, 9-20.	9.6	191
9	Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. Biochimie, 2018, 149, 79-91.	2.6	39
10	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. JCSM Rapid Communications, 2018, 1, 1-15.	1.6	3
11	Omegaâ€3 and omegaâ€3/curcuminâ€enriched fruit juices decrease tumour growth and reduce muscle wasting in tumourâ€bearing mice. JCSM Rapid Communications, 2018, 1, 1-10.	1.6	5
12	The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer. Clinical Nutrition, 2017, 36, 798-803.	5.0	22
13	Unifying diagnostic criteria for cachexia: An urgent need. Clinical Nutrition, 2017, 36, 910-911.	5.0	10
14	Novel targeted therapies for cancer cachexia. Biochemical Journal, 2017, 474, 2663-2678.	3.7	55
15	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. Frontiers in Physiology, 2017, 8, 92.	2.8	46
16	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. Frontiers in Physiology, 2017, 8, 184.	2.8	17
17	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. PeerJ, 2017, 5, e4109.	2.0	20
18	The Three Faces of Sarcopenia. Journal of the American Medical Directors Association, 2016, 17, 471-472.	2.5	18

#	Article	IF	Citations
19	The assessment of productivity in biomedical research. Annals of Medicine, 2016, 48, 631-633.	3.8	0
20	Conversion of leucine to Î²-hydroxy-Î²-methylbutyrate by Î±-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 68-78.	7.3	48
21	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	7.3	45
22	Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease. Journal of the American Medical Directors Association, 2016, 17, 789-796.	2.5	317
23	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <scp>II</scp> receptor inhibition and Î²â€2 agonist. International Journal of Cancer, 2016, 138, 2021-2029.	5.1	55
24	Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. Seminars in Cell and Developmental Biology, 2016, 54, 20-27.	5.0	58
25	Open source in cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 112-113.	7.3	2
26	Muscle wasting in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 221-225.	2.5	56
27	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	43
28	Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology, 2015, 22, 100-106.	3.5	231
29	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget, 2015, 6, 43202-43215.	1.8	78
30	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 315-320.	7.3	44
31	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	2.2	167
32	A differential pattern of gene expression in skeletal muscle of tumorâ€bearing rats reveals dysregulation of excitationâ€“contraction coupling together with additional muscle alterations. Muscle and Nerve, 2014, 49, 233-248.	2.2	20
33	Cachexia: a problem of energetic inefficiency. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 279-286.	7.3	72
34	Hypothalamic food intake regulation in a cancerâ€cachectic mouse model. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 159-169.	7.3	23
35	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	28.4	991
36	Recent Developments in Treatment of Cachexia. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 259-273.	0.6	1

#	Article	IF	Citations
37	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	2.5	24
38	The potential of ghrelin in the treatment of cancer cachexia. Expert Opinion on Biological Therapy, 2013, 13, 67-76.	3.1	35
39	Mechanisms and treatment of cancer cachexia. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, S19-S24.	2.6	44
40	A new look at an old drug for the treatment of cancer cachexia: Megestrol acetate. Clinical Nutrition, 2013, 32, 319-324.	5.0	37
41	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2770-2778.	2.4	83
42	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. International Journal of Oncology, 2013, 43, 886-894.	3.3	79
43	Central Melanin-Concentrating Hormone Influences Liver and Adipose Metabolism Via Specific Hypothalamic Nuclei and Efferent Autonomic/JNK1 Pathways. Gastroenterology, 2013, 144, 636-649.e6.	1.3	79
44	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. Journal of Lipid Research, 2013, 54, 3045-3051.	4.2	17
45	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncology Letters, 2012, 3, 185-189.	1.8	31
46	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 37-43.	7.3	115
47	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. E-SPEN Journal, 2012, 7, e135-e138.	0.5	3
48	Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutrition and Metabolism, 2012, 9, 76.	3.0	18
49	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clinical Nutrition, 2012, 31, 889-895.	5.0	37
50	Counteracting Inflammation: A Promising Therapy in Cachexia. Critical Reviews in Oncogenesis, 2012, 17, 253-262.	0.4	59
51	Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. International Journal of Cancer, 2012, 131, 2187-2196.	5.1	51
52	Are there any benefits of exercise training in cancer cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 73-76.	7.3	102
53	Myostatin: more than just a regulator of muscle mass. Drug Discovery Today, 2012, 17, 702-709.	6.4	105
54	Nutrition and cachexia. , 2012, , 185-194.		0

#	Article	IF	Citations
55	Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. International Journal of Molecular Medicine, 2011, 27, 15-24.	4.0	70
56	Sarcopenia With Limited Mobility: An International Consensus. Journal of the American Medical Directors Association, 2011, 12, 403-409.	2.5	884
57	Accounting Research: A Critical View Of The Present Situation And Prospects. Revista De Contabilidad-Spanish Accounting Review, 2011, 14, 9-34.	0.9	13
58	Fair value versus historical cost-based valuation for biological assets: predictability of financial information. Revista De Contabilidad-Spanish Accounting Review, 2011, 14, 87-113.	0.9	20
59	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. Experimental and Therapeutic Medicine, 2011, 2, 731-735.	1.8	16
60	Effects of Eicosapentaenoic Acid (EPA) Treatment on Insulin Sensitivity in an Animal Model of Diabetes: Improvement of the Inflammatory Status. Obesity, 2011, 19, 362-369.	3.0	80
61	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. Clinical Nutrition, 2011, 30, 33-37.	5.0	10
62	Anti-inflammatory therapies in cancer cachexia. European Journal of Pharmacology, 2011, 668, S81-S86.	3.5	63
63	Sirtuin 1 in skeletal muscle of cachectic tumourâ€bearing rats: a role in impaired regeneration?. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 57-62.	7.3	22
64	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 87-93.	7.3	138
65	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 95-104.	7.3	72
66	Interleukinâ€15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. Lipids, 2011, 46, 1033-1042.	1.7	25
67	Effects of formoterol on protein metabolism in myotubes during hyperthermia. Muscle and Nerve, 2011, 43, 268-273.	2.2	5
68	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia. , 2011, , 9-35.		16
69	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncology Reports, 2011, 25, 189-93.	2.6	33
70	Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) â€œcachexia-anorexia in chronic wasting diseasesâ€•and â€œnutrition in geriatricsâ€• Clinical Nutrition, 2010, 29, 154-159.	5.0	1,360
71	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clinical Nutrition, 2010, 29, 733-737.	5.0	27
72	Patterns of gene expression in muscle and fat in tumorâ€bearing rats: Effects of CRF2R agonist on cachexia. Muscle and Nerve, 2010, 42, 936-949.	2.2	5

#	Article	IF	Citations
73	Optimal management of cancer anorexia–cachexia syndrome. Cancer Management and Research, 2010, 2, 27.	1.9	57
74	Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants and Redox Signaling, 2010, 12, 365-380.	5.4	71
75	Consensus on Cachexia Definitions. Journal of the American Medical Directors Association, 2010, 11, 229-230.	2.5	134
76	Nutritional Recommendations for the Management of Sarcopenia. Journal of the American Medical Directors Association, 2010, 11, 391-396.	2.5	548
77	Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E191-E202.	3.5	208
78	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discovery Today, 2009, 14, 208-213.	6.4	61
79	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Letters, 2009, 583, 350-356.	2.8	33
80	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
81	The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2009, 3, 263-268.	1.3	162
82	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: Possible involvement on in vivo adipocyte differentiation. International Journal of Molecular Medicine, 2009, 24, 453-8.	4.0	23
83	Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. Anticancer Research, 2009, 29, 1315-7.	1.1	9
84	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle and Nerve, 2008, 37, 190-195.	2.2	21
85	Effects of ILâ€15 on Rat Brown Adipose Tissue: Uncoupling Proteins and PPARs. Obesity, 2008, 16, 285-289.	3.0	40
86	Cachexia: A new definition. Clinical Nutrition, 2008, 27, 793-799.	5.0	1,906
87	Novel approaches to the treatment of cachexia. Drug Discovery Today, 2008, 13, 73-78.	6.4	60
88	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. International Journal of Biochemistry and Cell Biology, 2008, 40, 1674-1678.	2.8	43
89	Potassium Channels are a New Target Field in Anticancer Drug Design. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 212-223.	1.6	46
90	Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of Î²2-Adrenergic Agonists. Cancer Research, 2007, 67, 6512-6519.	0.9	43

#	Article	IF	Citations
91	Mechanisms to explain wasting of muscle and fat in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2007, 1, 293-298.	1.3	42
92	Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1028-1036.	2.4	9
93	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters, 2007, 245, 144-148.	7.2	68
94	Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2007, 12, 555-570.	2.4	7
95	Targets in clinical oncology: the metabolic environment of the patient. Frontiers in Bioscience - Landmark, 2007, 12, 3024.	3.0	18
96	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
97	Protein breakdown on whole-body and organ level in non-cachectic tumour-bearing mice undergoing surgery. Clinical Nutrition, 2007, 26, 483-490.	5.0	9
98	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clinical Nutrition, 2007, 26, 614-618.	5.0	58
99	Antiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?. Clinical Nutrition, 2007, 26, 658-661.	5.0	29
100	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 2007, 30, 1239-45.	3.3	15
101	Cancer Cachexia and Fat Metabolism. , 2006, , 459-466.		2
102	The Role of Cytokines in Cancer Cachexia. , 2006, , 467-475.		5
103	Interleukin-15 increases glucose uptake in skeletal muscle An antidiabetogenic effect of the cytokine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1613-1617.	2.4	79
104	The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. FEBS Letters, 2006, 580, 691-696.	2.8	26
105	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: A role in muscle wasting?. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 253-258.	2.4	16
106	Effects of interleukin-15 on lipid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 37-42.	2.4	50
107	Cytokines as Mediators and Targets for Cancer Cachexia. Cancer Treatment and Research, 2006, 130, 199-217.	0.5	50
108	Roles of Skeletal Muscle and Peroxisome Proliferator-Activated Receptors in the Development and Treatment of Obesity. Endocrine Reviews, 2006, 27, 318-329.	20.1	34

#	Article	IF	Citations
109	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	1.8	149
110	Training Depletes Muscle Glutathione in Patients with Chronic Obstructive Pulmonary Disease and Low Body Mass Index. Respiration, 2006, 73, 757-761.	2.6	52
111	Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: Evidence for a skeletal muscle-to-fat signaling pathway. Cell Biology International, 2005, 29, 449-457.	3.0	148
112	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition, 2005, 21, 977-985.	2.4	86
113	Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. Medicinal Research Reviews, 2005, 25, 49-65.	10.5	162
114	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. ChemInform, 2005, 36, no.	0.0	1
115	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. International Journal of Biochemistry and Cell Biology, 2005, 37, 1084-1104.	2.8	144
116	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 1609-1619.	2.8	38
117	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 2036-2046.	2.8	89
118	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. FEBS Letters, 2005, 579, 717-722.	2.8	48
119	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2005, 579, 1646-1652.	2.8	109
120	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963-7.	4.0	8
121	Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncology Reports, 2005, 14, 257-63.	2.6	61
122	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. International Journal of Molecular Medicine, 2005, 16, 471-6.	4.0	54
123	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2
124	The Pharmacological Treatment of Cachexia. Current Drug Targets, 2004, 5, 265-277.	2.1	41
125	Anticachectic Effects of Formoterol. Cancer Research, 2004, 64, 6725-6731.	0.9	148
126	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95

#	Article	IF	Citations
127	The systemic inflammatory response is involved in the regulation of K+channel expression in brain via TNF-Î±-dependent and -independent pathways. FEBS Letters, 2004, 572, 189-194.	2.8	26
128	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
129	Catabolic mediators as targets for cancer cachexia. Drug Discovery Today, 2003, 8, 838-844.	6.4	43
130	Impaired voltage-gated K+channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
131	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
132	Cancer cachexia: the molecular mechanisms. International Journal of Biochemistry and Cell Biology, 2003, 35, 405-409.	2.8	102
133	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine, 2003, 22, 1-4.	3.2	37
134	Increased tumour necrosis factorâ€Î± plasma levels during moderate-intensity exercise in COPD patients. European Respiratory Journal, 2003, 21, 789-794.	6.7	143
135	The use of financial accounting information and firm performance: an empirical quantification for farms. Accounting and Business Research, 2003, 33, 251-273.	1.8	41
136	Cytokines in the pathogenesis of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	114
137	Sepsis induces DNA fragmentation in rat skeletal muscle. European Cytokine Network, 2003, 14, 256-9.	2.0	12
138	Overexpression of Interleukin-15 Induces Skeletal Muscle Hypertrophy in Vitro: Implications for Treatment of Muscle Wasting Disorders. Experimental Cell Research, 2002, 280, 55-63.	2.6	186
139	The role of uncoupling proteins in pathophysiological states. Biochemical and Biophysical Research Communications, 2002, 293, 1145-1152.	2.1	90
140	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 2002, 1570, 33-37.	2.4	87
141	TNF-Î± modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Letters, 2002, 175, 181-185.	7.2	33
142	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2002, 188, 53-58.	7.2	1
143	Tumor necrosis factor-Î± exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 66-72.	4.1	55
144	Branched-chain amino acids: A role in skeletal muscle proteolysis in catabolic states?. Journal of Cellular Physiology, 2002, 191, 283-289.	4.1	38

#	Article	IF	Citations
145	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 17-24.	2.4	146
146	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters, 2001, 167, 33-38.	7.2	88
147	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-Î±?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1499, 249-256.	4.1	23
148	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. FEBS Letters, 2001, 505, 255-258.	2.8	29
149	Metabolic interrelationships between liver and skeletal muscle in pathological states. Life Sciences, 2001, 69, 1345-1361.	4.3	21
150	Accounting information and the prediction of farm non-viability. European Accounting Review, 2001, 10, 73-105.	3.8	41
151	Reduced Muscle Redox Capacity after Endurance Training in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1114-1118.	5.6	158
152	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. Journal of Cellular Physiology, 2000, 184, 380-384.	4.1	60
153	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. Journal of Nutritional Biochemistry, 2000, 11, 431-435.	4.2	31
154	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
155	The role of cytokines in cancer cachexia. , 1999, 19, 223-248.		183
156	Leptin and tumor growth in rats. , 1999, 81, 726-729.		41
157	Resveratrol, a Natural Product Present in Wine, Decreases Tumour Growth in a Rat Tumour Model. Biochemical and Biophysical Research Communications, 1999, 254, 739-743.	2.1	246
158	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Molecular and Cellular Endocrinology, 1998, 142, 183-189.	3.2	104
159	Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Letters, 1998, 130, 19-27.	7.2	69
160	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
161	Short-term effects of leptin on lipid metabolism in the rat. FEBS Letters, 1998, 431, 371-374.	2.8	27
162	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Letters, 1998, 436, 415-418.	2.8	64

#	Article	IF	Citations
163	In the rat, tumor necrosis factor Î± administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Letters, 1998, 440, 348-350.	2.8	88
164	Catabolic proinflammatory cytokines. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 245-251.	2.5	61
165	Controversy in Basic Sciences Is TNF Really Involved in Cachexia?. Cancer Investigation, 1997, 15, 47-54.	1.3	24
166	TNF Can Directly Induce the Expression of Ubiquitin-Dependent Proteolytic System in Rat Soleus Muscles. Biochemical and Biophysical Research Communications, 1997, 230, 238-241.	2.1	159
167	Lipid metabolism in tumour-bearing mice:. Molecular and Cellular Endocrinology, 1997, 132, 93-99.	3.2	27
168	Sequential changes in lipoprotein lipase activity and lipaemia induced by the Yoshida AH-130 ascites hepatoma in rats. Cancer Letters, 1997, 116, 159-165.	7.2	11
169	Comparative effects of Î²2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Letters, 1997, 115, 113-118.	7.2	44
170	Journey from cachexia to obesity by TNF. FASEB Journal, 1997, 11, 743-751.	0.5	123
171	The ubiquitin system: A role in disease?. , 1997, 17, 139-161.		8
172	The metabolic basis of cancer cachexia. , 1997, 17, 477-498.		146
173	The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends in Pharmacological Sciences, 1996, 17, 223-226.	8.7	67
174	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Letters, 1996, 99, 7-14.	7.2	32
175	Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Molecular and Cellular Biochemistry, 1996, 165, 17-23.	3.1	18
176	Marked hyperlipidaemia in rats bearing the Yoshida AH-130 ascites hepatoma. Biochemical Society Transactions, 1995, 23, 492S-492S.	3.4	2
177	Muscle wasting associated with cancer cachexia is linked to an important activation of the atp-dependent ubiquitin-mediated proteolysis. International Journal of Cancer, 1995, 61, 138-141.	5.1	101
178	Metabolic effects of tumour necrosis factor-Î± on rat brown adipose tissue. Molecular and Cellular Biochemistry, 1995, 143, 113-118.	3.1	10
179	Lipopolysaccharide (LPS) increases their vivo oxidation of branched-chain amino acids in the rat: A cytokine-mediated effect. Molecular and Cellular Biochemistry, 1995, 148, 9-15.	3.1	20
180	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Letters, 1995, 91, 73-78.	7.2	24

#	Article	IF	Citations
181	Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Letters, 1995, 95, 33-38.	7.2	52
182	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Letters, 1995, 97, 25-32.	7.2	21
183	Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Letters, 1994, 76, 1-4.	7.2	48
184	Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 1994, 87, 123-130.	7.2	9
185	Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Letters, 1994, 338, 311-318.	2.8	120
186	Anti-Tumour Necrosis Factor-Î± Treatment Interferes with Changes in Lipid Metabolism in a Tumour Cachexia Model. Clinical Science, 1994, 87, 349-355.	4.3	70
187	Tumour necrosis factor-Î± increases the ubiquitinization of rat skeletal muscle proteins. FEBS Letters, 1993, 323, 211-214.	2.8	125
188	A flow cytometric study of the rat Yoshida AH-130 ascites hepatoma. Cancer Letters, 1993, 72, 169-173.	7.2	13
189	The role of cytokines in muscle wasting: Its relation with cancer cachexia. Medicinal Research Reviews, 1992, 12, 637-652.	10.5	77
190	Metabolic Effects of Tumour Necrosis Factor-Î± (Cachectin) and Interleukin-1. Clinical Science, 1989, 77, 357-364.	4.3	129
191	Formoterol May Activate Rat Muscle Regeneration During Cancer Cachexia. Insciences Journal, 0, , 1-17.	0.7	9